Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer
NCT ID: NCT06726291
Last Updated: 2024-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
84 participants
INTERVENTIONAL
2024-02-26
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of the study is to learn if the drug is able to avoid the occurrence of vomiting and post- nausea chemotherapy within 120 hours after cycle 1 with carboplatin and paclitaxel with or without immunotherapy.
Partecipants will take the drug before the chemotherapy/immunotherapy (single dose at day one of each cycle of therapy, that is one capsule before treatment). The entire duration of participation in the study may extend to the fourth cycle of chemotherapy/immunotherapy.
Patients will fill in questionnaires and keep a diary of the number and intensity of symptoms (vomiting and nausea).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
CINV (chemotherapy-induced nausea and vomiting) is the most dreaded side effect before starting chemotherapy in both genders and across all age classes, and women are significantly more concerned about it than men. Patients with gynecological cancer represent an extremely challenging population in which to treat or control CINV. Indeed, female sex is associated with a higher risk of CINV. In addition, gynecological malignancies often disseminate in the abdomen, increasing the emetogenic potential of chemotherapies. Thus, these patients are at a relatively high risk of experiencing CINV.
This is a phase IV, multicentric, single arm study using a fixed dose combination of netupitant and palonsetron NEPA in the treatment of chemo-naive patients ≥18 years of age with histologically or cytologically confirmed diagnosis of endometrial cancer who will receive a single line of taxane-platinum combination with or without immunotherapy.
This study aims also to evaluate patients' expectation and perception of CINV and other chemotherapy side effects (CSEs); impact of CINV and others CSEs on quality of life, health, family and personal relationships, daily activities and employment in patients with endometrial cancer receiving paclitaxel and carboplatin regimen. The agreement between patients' assessment of CINV and other CSEs as reported in a self-report scale and what they referred to clinicians about nausea and CSEs at the following chemotherapy cycle and agreement between patients' expectation of CINV and other CSEs before initiating of chemotherapy and the side effects that they actually experienced during chemotherapy will be also evaluated.
Patients will be observed over a duration of 4 cycles. The primary endpoint will be assessed at cycle 1.
This study will enroll female patients ≥18 years of age with histologically or cytologically confirmed diagnosis of endometrial cancer who will receive a single line of taxane-platinum combination therapy with or without immunotherapy. This includes chemotherapy naïve patients who will receive taxane-platinum combination therapy in adjuvant setting or chemotherapy naïve patients who will receive first line taxane-platinum combination therapy with or without immunotherapy for primary advanced or recurrent disease. The planned number of patients is 84, and 8 centers will be involved in the trial.
Primary objective: To evaluate effectiveness of a single oral dose of NEPA in terms of complete response (CR: no emesis, no rescue medication) in the overall phase (0-120h) at cycle 1 in chemotherapy-naïve patients with endometrial cancer receiving paclitaxel and carboplatin with or without immunotherapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
antiemetic
Patients who will receive a fixed dose combination of netupitant and palonsetron, NEPA
NEPA (300mg netupitant/0.5mg palonosetron)
a single dose (capsule) of NEPA (300mg netupitant/0.5 palonosetron) at day 1 for a maximum of 4 cycles
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NEPA (300mg netupitant/0.5mg palonosetron)
a single dose (capsule) of NEPA (300mg netupitant/0.5 palonosetron) at day 1 for a maximum of 4 cycles
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has histologically or cytologically proven endometrial cancer
* Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
* Adequate organ function allowing the patient to receive taxane-platinum combination therapy with or without immunotherapy according to clinical practice and opinion of treating physician
* Naive to chemotherapy
* Women of child-bearing potential must have a negative pregnancy test (urine). Female patients are considered of child-bearing potential following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Patients are considered to not be of child-bearing potential if they have a history of tubal ligation or hysterectomy or are post-menopausal with a minimum of 1 year without menses. Patients of child-bearing potential must agree to adequate birth control if conception is possible during the study and for 6 months after the last dose; in this case, patients must take a monthly pregnancy test for the duration of the study
Exclusion Criteria
* will be scheduled to radiation therapy to the abdomen or pelvis within 1 week before day 1 or between day 1 and 5
* Will be scheduled to undergo bone marrow or stem-cell transplant
* Chronic systemic corticosteroid use
* Brain metastasis
* Subject is considered a poor medical risk due to a serious, uncontrolled medical disorder
* History or predisposition to cardiac conduction abnormalities, torsade des pointes or severe cardiovascular diseases
* Subject is pregnant or breastfeeding or is expecting to conceive children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of study treatment
* They have any known hypersensitivity or contraindication to the components of the study drugs (hypersensitivity to the active substance or to any of the excipients contained in the product, as listed in the relevant section of the summary of product characteristics)
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Monika Ducceschi, MD
Role: PRINCIPAL_INVESTIGATOR
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ASST Spedali Civili di Brescia
Brescia, BS, Italy
ASST Lecco - A. Manzoni Hospital
Lecco, LC, Italy
Istituto Oncologico Veneto
Padua, PD, Italy
Centro di Riferimento Oncologico (CRO) IRCCS
Aviano, PN, Italy
Azienda Ospedaliera Ordine Mauriziano di Torino
Torino, TO, Italy
AOU Città della Salute e della Scienza di Torino
Torino, TO, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, , Italy
Istituto Europeo di Oncologia
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Germana Tognon, MD
Role: primary
Alessandra Crippa, MD
Role: primary
Giulia Tasca, MD
Role: primary
Michele Bartoletti, MD
Role: primary
Dionnyssios Katsaros, MD
Role: primary
Monika Ducceschi, MD
Role: primary
Mara Mantiero, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-504150-35-00
Identifier Type: CTIS
Identifier Source: secondary_id
INT 121-23 NOEME
Identifier Type: -
Identifier Source: org_study_id